Silo Pharma, Inc. (NASDAQ:SILO) Short Interest Update

Silo Pharma, Inc. (NASDAQ:SILO) saw a large drop in short interest during the month of March. As of March 13th, there was short interest totaling 319,975 shares, a drop of 45.6% from the February 26th total of 588,548 shares. Currently, 2.5% of the shares of the company are sold short. Based on an average trading volume of 234,469 shares, the short-interest ratio is currently 1.4 days.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silo Pharma in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Silo Pharma Trading Down 0.3%

Shares of NASDAQ SILO opened at $0.38 on Friday. The company has a 50 day simple moving average of $0.34 and a two-hundred day simple moving average of $0.45. The stock has a market cap of $5.05 million, a price-to-earnings ratio of -0.40 and a beta of 0.39. Silo Pharma has a 12 month low of $0.22 and a 12 month high of $1.35.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. AdvisorShares Investments LLC grew its position in Silo Pharma by 98.0% during the 3rd quarter. AdvisorShares Investments LLC now owns 364,878 shares of the company’s stock worth $252,000 after purchasing an additional 180,642 shares during the period. Virtu Financial LLC purchased a new position in shares of Silo Pharma during the 3rd quarter valued at about $74,000. DRW Securities LLC acquired a new position in shares of Silo Pharma in the 4th quarter valued at about $113,000. Geode Capital Management LLC lifted its holdings in shares of Silo Pharma by 134.6% in the 4th quarter. Geode Capital Management LLC now owns 92,905 shares of the company’s stock valued at $32,000 after buying an additional 53,309 shares during the period. Finally, Anson Funds Management LP purchased a new stake in shares of Silo Pharma in the third quarter worth about $657,000. 5.58% of the stock is currently owned by institutional investors and hedge funds.

Silo Pharma Company Profile

Silo Pharma, Inc (NASDAQ:SILO) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel psychedelic and related synthetic therapies. Headquartered in New York City, the company applies proprietary chemistry and targeted drug delivery approaches to advance candidates that address critical unmet needs across oncology, neurology and mental health.

The company’s preclinical and early-stage clinical pipeline comprises several programs that explore serotonin receptor modulators, synthetic analogs of classic psychoactive compounds and neuroprotective agents.